- A Kyowa Kirin afirma o compromisso de desenvolver o rocatinlimab como um ativo diferenciado de mudança de vida com potencial de mercado significativo.
- Read more »
Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique
- Kyowa Kirin réaffirme sa volonté de développer le rocatinlimab comme un traitement innovant capable d’améliorer significativement la vie des patients, tout en [...] Read more »
Kyowa Kirin erlangt Kontrolle über Entwicklungs- und Kommerzialisierungsprogramm für Rocatinlimab wieder, zeigt starkes Engagement im Bereich des ungedeckten medizinischen Bedarfs bei atopischer Dermatitis
- Kyowa Kirin bestätigt Engagement für die Entwicklung von Rocatinlimab als lebensveränderndes differenziertes Feld mit bedeutendem Marktpotenzial.
- Read more »
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
- Kyowa Kirin affirms commitment to developing rocatinlimab as a life–changing differentiated asset with significant market potential.
- Rocatinlimab’s novel approach as an investigational [...] Read more »
Countdown for a Cure Partners with Dr. Taz Bhatia M.D. and hol+ to Advance Mitochondrial Research and Awareness
ATLANTA, Jan. 23, 2026 (GLOBE NEWSWIRE) — Dr. Taz Bhatia M.D., a nationally recognized integrative medicine physician, author, and founder of hol+, has partnered with nonprofit Countdown for a Cure (CFAC) to help advance [...] Read more »
Attindas Hygiene Partners Amplia Parceira na Europa com Importante Aquisição
RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners dá um passo importante para sua estratégia de crescimento hoje com a aquisição da Societá Italiana [...] Read more »
Attindas Hygiene Partners renforce sa position en Europe grâce à une acquisition stratégique
RALEIGH, Caroline du Nord, 10 janv. 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners exécute aujourd’hui une étape majeure dans sa stratégie de croissance avec l’acquisition de Società [...] Read more »
Attindas Hygiene Partners baut mit bedeutender Akquisition seine Position in Europa aus
RALEIGH, North Carolina, Jan. 10, 2026 (GLOBE NEWSWIRE) — Die Wachstumsstrategie von Attindas Hygiene Partners hat heute mit der Übernahme von Società Italiana Lavorazione Cellulosa (SILC S.p.A.) einen wichtigen [...] Read more »
Attindas Hygiene Partners Expands European Position with Key Acquisition
RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners’ growth strategy realized an important step forward today with its acquisition of Societá Italiana Lavorazione Cellulosa (SILC [...] Read more »
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
- REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
- After 12 weeks [...] Read more »
Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
WASHINGTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3–Marburg Vaccine to Ethiopia to support the [...] Read more »
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »
شركة Profound Medical توقع اتفاقية توزيع حصرية لمنتجات TULSA-PRO®وSonalleve® مع شركة Al Faisaliah Medical Systems في المملكة العربية السعودية
الاتفاقية تفتح المجال أمام علاجات [...] Read more »
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Agreement creates runway for Profound’s incision–free and radiation–free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East
Read more »
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical–stage biopharmaceutical company [...] Read more »